Add Company
Join Now

MSI STEM RandD Consortium Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • MSI STEM RandD Consortium's estimated annual revenue is currently $918k per year.(i)
  • MSI STEM RandD Consortium's estimated revenue per employee is $61,200

Employee Data

  • MSI STEM RandD Consortium has 15 Employees.(i)
  • MSI STEM RandD Consortium grew their employee count by 15% last year.

MSI STEM RandD Consortium's People

NameTitleEmail/Phone
1
Director Research DevelopmentReveal Email/Phone
2
Research Development AssociateReveal Email/Phone
3
President & CEOReveal Email/Phone
4
ChairmanReveal Email/Phone
5
Sharepoint DeveloperReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.2M39-22%N/AN/A
#2
$3.9M487%N/AN/A
#3
$0.3M6-33%N/AN/A
#4
$14M13710%N/AN/A
#5
$29.1M2599%N/AN/A
#6
$3.3M418%N/AN/A
#7
$18M160-9%N/AN/A
#8
$18.6M166-6%N/AN/A
#9
$1.7M24-31%N/AN/A
#10
$3.8M4615%N/AN/A
Add Company

What Is MSI STEM RandD Consortium?

MSRDC serves as a strategic asset, solutions provider, and research development partner to more than 60 minority-serving research institutions, federal partners, and private industry collaborators. Our members use a combination of basic, applied, and advanced research to pioneer groundbreaking solutions that drive innovation forward.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$918k

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MSI STEM RandD Consortium News

2022-04-20 - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer

The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H ... Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

2022-04-13 - The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients. The...

2022-03-22 - FDA Approves Merck's KEYTRUDA® (pembrolizumab) for ...

Among the 90 patients with MSI-H or dMMR endometrial carcinoma enrolled in ... Complications of Allogeneic Hematopoietic Stem Cell...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M150%$3M
#2
$15M15-17%N/A
#3
$1.3M150%N/A
#4
$1.8M157%N/A
#5
$35M150%N/A